AmCad BioMed (4188) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 安克

AmCad BioMed (4188) reported revenue of NT$2.1 million for Oct 2026, -16.6% year on year and -6.3% from the previous month. Revenue for Jan–Oct 2026 was NT$23.2 million (-16.8% year on year).

In Oct 2026, it ranked No. 142 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$3.4 million24/10Nov 2024 NT$6.9 millionDec 2024 NT$7.8 millionJan 2025 NT$2.3 millionFeb 2025 NT$2.3 million25/02Mar 2025 NT$2.2 millionApr 2025 NT$2.8 millionMay 2025 NT$2.4 millionJun 2025 NT$3 million25/06Jul 2025 NT$2.1 millionAug 2025 NT$2.3 millionSep 2025 NT$6 millionOct 2025 NT$2.5 million25/10Nov 2025 NT$1.3 millionDec 2025 NT$1.2 millionJan 2026 NT$2.9 millionFeb 2026 NT$1.6 million26/02Mar 2026 NT$1.9 millionApr 2026 NT$2.7 millionMay 2026 NT$2.2 millionJun 2026 NT$1.9 million26/06Jul 2026 NT$3.3 millionAug 2026 NT$2.4 millionSep 2026 NT$2.3 millionOct 2026 NT$2.1 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$2.1 million-16.6%-6.3%
Sep 2026NT$2.3 million-62.2%-5.9%
Aug 2026NT$2.4 million+2.9%-28.1%
Jul 2026NT$3.3 million+56.5%+80.2%
Jun 2026NT$1.9 million-38.3%-15.2%
May 2026NT$2.2 million-8.7%-18.7%
Apr 2026NT$2.7 million-3.0%+39.8%
Mar 2026NT$1.9 million-13.1%+23.7%
Feb 2026NT$1.6 million-31.6%-46.7%
Jan 2026NT$2.9 million+26.5%+138.1%
Dec 2025NT$1.2 million-84.3%-6.3%
Nov 2025NT$1.3 million-81.1%-48.5%
Oct 2025NT$2.5 million-25.6%-57.5%
Sep 2025NT$6 million+73.9%+156.0%
Aug 2025NT$2.3 million-7.5%+9.4%
Jul 2025NT$2.1 million-53.3%-28.9%
Jun 2025NT$3 million-50.1%+25.4%
May 2025NT$2.4 million-67.4%-13.6%
Apr 2025NT$2.8 million-8.3%+25.3%
Mar 2025NT$2.2 million-1.6%-2.6%
Feb 2025NT$2.3 million-35.0%-1.6%
Jan 2025NT$2.3 million-1.7%-70.5%
Dec 2024NT$7.8 million-23.7%+13.1%
Nov 2024NT$6.9 million+36.9%+103.0%
Oct 2024NT$3.4 million-58.0%-0.8%

Jan–Oct 2026 cumulative: NT$23.2 million (-16.8% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: AmCad BioMed vs PEC / AmCad BioMed vs Lotus Pharm / AmCad BioMed vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16